Ramsay (ASX:RHC) share price falls 6% amid reports of COVID battle plan

COVID-19 has imposed a major challenge on the private hospital operator.

| More on:
Graph showing a fall in share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ramsay Health Care Limited (ASX: RHC) share price is suffering today amid a broader market sell-off.

Meanwhile, reports have emerged that the private hospital operator has its sights set on a hiring spree, bringing in graduate nurses to fight against a COVID-19-exacerbated shortage.

At the time of writing, the Ramsay Health Care share price is $67.58, 5.76% lower than its previous close.

For context, the S&P/ASX 200 Index (ASX: XJO) has slumped 2.78% today, while the All Ordinaries Index (ASX: XAO) is down 2.83%.

Let's take a closer look at Ramsay's apparent plan to staff its hospitals through yet another COVID-19 outbreak.

Ramsay share price slides amid planned hiring spree

According to reporting by The Australian, Ramsay is planning to onboard its highest intake of graduate nurses to battle a shortage of staff made worse by the pandemic.

It expects to employ 550 new graduates – 25% more than it did during 2021.

Previous research by the federal government – conducted in 2014 – forecasts a shortfall of 85,000 nurses by 2025 and 123,000 by 2030.

On top of that, CEO of Ramsay's Australian operations, Carmel Monaghan was quoted as saying that the pandemic has worsened the shortage:

Like all industries, we see the workforce as our most significant challenge for the next few years. Supply has been constrained with borders closed and staff furloughed due to COVID.

Monaghan also stated that some nurses refused to be vaccinated against COVID-19, further exacerbating the shortage.

The Australian noted a shortage of nurses may block the company's hospitals from bouncing back to their full elective surgery capacity.

Elective surgeries are a major income source for Ramsay's private hospitals. In its results for financial year 2021, Ramsay reported that a 90-day restriction on elective surgeries in Victoria had a $70 million impact on the company's earnings before interest and tax.

Similar restrictions were put in place in New South Wales over the first half of financial year 2022 and were one reason behind a 39.5% fall in the company's unaudited net profit after tax for the first quarter of financial year 2022.

Thus, it likely goes without saying that the market will be watching the Ramsay Health Care share price when it releases its results for the first half of financial year 2022.

Monaghan reportedly told The Australian that the company has already received expressions of interest from 500 graduate nurses.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Healthcare Shares

Are CSL and this ASX 200 healthcare stock buys in January?

Is now a good time to pick up these shares? Let's see what analysts are saying.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Communication Shares

2 ASX shares expected to report strong earnings this quarter

Analysts expect a strong set of upcoming numbers for these ASX heavyweights

Read more »

A women has her eyes checked at the optometrist.
Healthcare Shares

Is Medibank stock a good buy?

Can this company provide healthy returns?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »